Botulism
16
0
0
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
17%
2 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (16)
BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
Study of the Drug B11-FC (Botulism Treatment)
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults
Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B
Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
Study of Human Botulism Immunoglobulin in Infants With Botulism
Phase 1 PK Study of XOMA 3AB
Treatment of Survivors After Botulism Outbreak
Botulism Outbreak in Thailand (Episode II)